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Predictors of neonatal abstinence 
syndrome in buprenorphine exposed  
newborn: can cord blood buprenorphine 
metabolite levels help?
Darshan Shah1*, Stacy Brown2, Nick Hagemeier3, Shimin Zheng4, Amy Kyle2, Jason Pryor5, Nilesh Dankhara1 
and Piyuesh Singh1
Abstract 
Background: Buprenorphine is a semi-synthetic opioid used for the treatment of opioid dependence. Opioid use, 
including buprenorphine, has been increasing in recent years, in the general population and in pregnant women. 
Consequently, there has been a rise in frequency of neonatal abstinence syndrome (NAS), associated with buprenor-
phine use during pregnancy. The purpose of this study was to investigate correlations between buprenorphine and 
buprenorphine-metabolite concentrations in cord blood and onset of NAS in buprenorphine exposed newborns.
Methods: Nineteen (19) newborns who met inclusion criteria were followed after birth until discharge in a double-
blind non-intervention study, after maternal consent. Cord blood and tissue samples were collected and analyzed by 
liquid chromatography–mass spectrometry (LC–MS) for buprenorphine and metabolites. Simple and multiple logistic 
regressions were used to examine relationships between buprenorphine and buprenorphine metabolite concentra-
tions in cord blood and onset of NAS, need for morphine therapy, and length of stay.
Results: Each increase in 5 ng/ml level of norbuprenorphine in cord blood increases odds of requiring treatment by 
morphine 2.5 times. Each increase in 5 ng/ml of buprenorphine-glucuronide decreases odds of receiving morphine 
by 57.7 %. Along with concentration of buprenorphine metabolites, birth weight and gestational age also play impor-
tant roles, but not maternal buprenorphine dose.
Conclusions: LC–MS analysis of cord blood concentrations of buprenorphine and metabolites is an effective way to 
examine drug and metabolite levels in the infant at birth. Cord blood concentrations of the active norbuprenorphine 
metabolite and the inactive buprenorphine-glucuronide metabolite show promise in predicting necessity of treat-
ment of NAS. These finding have implications in improving patient care and reducing healthcare costs if confirmed in 
a larger sample.
Keywords: Buprenorphine, Neonatal abstinence syndrome, NAS, Cord blood, Metabolites
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
In recent years, there has been a rise in opioid-related 
drug use among pregnant women, specifically buprenor-
phine-containing medications (Eichel and Johannemann 
2014). Buprenorphine is Food and Drug Administration 
(FDA)-approved for detoxification and maintenance 
therapy for opioid dependence, and is more frequently 
used in pregnancy than methadone due to better neona-
tal outcomes (Gugelmann and Nelson 2012; Jones et  al. 
2010; Prabhakar 2014). Maternal substance use disor-
der and development of neonatal abstinence syndrome 
(NAS) poses significant health problems for both woman 
and newborn with probable long term neurodevelopment 
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adverse outcomes (Burns and Mattick 2007; Kellogg et al. 
2011; SAMHSA 2010). From 1995 to 2009, cases of NAS 
have increased from 0.4 to 4.4 discharges per 1000 live 
births, representing what many feel is a national pub-
lic health epidemic (Burns and Mattick 2007; Kellogg 
et al. 2011; SAMHSA 2010). Despite the rise in numbers 
for opioid-related NAS, predicting which infants will 
develop NAS following prenatal opioid exposure remains 
clinically difficult. Uncertainty of prediction of NAS 
requires all infants exposed to opioids during pregnancy 
to stay in the hospital for 5 days, which further increases 
cost of care. To that end, we investigated the possibility of 
drug-concentration and metabolite-concentration meas-
urements as a predictor for the development and sever-
ity of NAS in exposed infants. In this study, we examine 
correlates of newborn cord blood buprenorphine and 
metabolite concentrations and the need to initiate opioid 
replacement therapy in the newborn, maternal buprenor-
phine dose, total morphine dose required for withdrawal, 
the duration of replacement therapy, and the length of 
neonatal intensive care unit (NICU) stay. Buprenorphine 
is metabolized by a Phase I oxidation to norbuprenor-
phine, which is a more potent mu-opioid agonist com-
pared to buprenorphine, and Phase II metabolites include 
inactive glucuronide forms of buprenorphine and nor-
buprenorphine, all of which are monitored in our study 
(Oechsler and Skopp 2010). Additionally, we utilized a 
unique sample matrix, the newborn cord blood, in order 
to ensure measurable concentrations of the water-soluble 
metabolites. This work presents a newer approach for 
investigating predictors of NAS, and utilizes state-of-the-
art analytical technology (LC–MS) with a sample matrix 
suitable for the quantification of drug metabolites.
Methods
Clinical sample collection
The protocol for this project was approved by our uni-
versity’s Institutional Review Board (IRB), and repre-
sented a prospective, double-blind, non-interventional 
study. Women undergoing substance use disorder ther-
apy were identified by history on presentation to the 
labor and delivery unit. Informed consent was obtained 
prior to delivery for those who met inclusion criteria 
for study. Inclusion criteria were gestational age more 
than 36  weeks, absence of congenital anomaly and no 
poly substance use. After delivery, cord blood was col-
lected in ETDA–treated tubes and stored in a labora-
tory freezer (−20  °C) until analysis. Batches of samples 
were dispatched to the liquid chromatography–mass 
spectrometry (LC–MS) laboratory for quantification of 
buprenorphine and related metabolites. Analysts were 
blinded to maternal medication history. Cord tissue sam-
ples were also collected from all neonates and sent to a 
separate laboratory as per institutional guidelines. All 
neonates were then followed based on hospital protocol 
for the development of NAS, diagnosed using the Finne-
gan scoring system at 4  h intervals by trained nursing 
staff (Finnegan et al. 1975). Neonates with two Finnegan 
scores greater than 10, consecutively verified by separate 
nursing staff members, were transferred to the NICU, and 
started on morphine treatment. Morphine was started at 
0.1 mg/kg every 4 h orally. Infants were weaned on doses 
of morphine at a rate of 10–20 % per day when Finnegan 
scores were below 7 for 24  h, and based on the infant’s 
clinical examination at the discretion of attending neo-
natologist. Morphine was discontinued when the dose 
reached less than 0.03 mg/kg per dose. Once weaned from 
morphine therapy, infants were monitored for 48 h prior 
to discharge. Results of cord blood metabolite were not 
available to clinical staff that cared for infants exposed to 
maternal drugs, but results of cord tissue were available.
Analysis of cord blood samples
Cord blood samples were spiked with deuterium-
labeled internal standards purchased from Cerilliant 
(RoundRock, TX). Samples were subjected to protein 
precipitation and solid-phase extraction (SPE) using 
Strata-X Drug B cartridges from Phenomenex (Tor-
rance, CA). Chromatographic separation was carried out 
using a Phenomenex Kinetex C18 column (1.9 micron, 
2.1  ×  50  mm), and mass spectrometric detection was 
achieved using a Shimadzu LCMS–IT–TOF system oper-
ating in positive electrospray (ESI) mode (Columbia, 
MD). The LC–MS method utilized has been previously 
validated and published (Kyle et al. 2015).
Statistical methods
Patient specific data were entered into a Microsoft Excel 
spreadsheet, cleaned, and thereafter imported into IBM 
SPSS Statistics version 20 (Armonk, NY) for analysis. 
Descriptive statistics were calculated for all variables. 
Simple logistic regressions were performed to assess the 
relationship between buprenorphine and metabolite cord 
blood concentrations and neonatal and maternal charac-
teristics and necessity (yes/no) of morphine therapy. We 
converted odds ratios (OR) to effect size (ES) to find real 
associations, rather than p value to assess statistical sig-
nificance, due to the study’s small sample size. Multiple 
logistic regressions were conducted for norbuprenor-
phine and buprenorphine-glucuronide cord blood con-
centration based on simple logistic regression.
Results
Patient population
A total of 19 women were enrolled for this study. Fifteen 
women were on Subutex™ (buprenorphine) and 4 were 
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on Suboxone™ (buprenorphine and naloxone). All infants 
were from gestational age 36–41.2  weeks with mean of 
38.5  weeks. Demographics of infants and their course 
and results from the LC–MS cord blood analysis are pre-
sented in Table 1. All women had history of smoking but 
no poly drug use.
Cord blood concentrations and opioid therapy 
characteristics
Table  2 presents sample descriptive statistics and out-
comes of simple logistic regression analyses examining 
relationships between buprenorphine and metabolite 
cord blood concentrations and neonatal and maternal 
characteristics, and necessity (yes/no) of morphine ther-
apy. We converted odds ratios (OR) to effect size due to 
small sample size. Based on effect size, gestational age 
(4  weeks), birth weight (kg), norbuprenorphine con-
centration (5  ng/ml) and buprenorphine-glucuronide 
concentration (5  ng/ml) were associated with necessity 
(yes/no) of morphine therapy. Associations were strong-
est for birth weight (kg) and buprenorphine-glucuro-
nide concentration (5  ng/ml). However, maternal daily 
buprenorphine dose, buprenorphine concentration (ng/
ml) and norbuprenorphine-glucuronide concentration 
(ng/ml) were not associated with necessity of morphine 
therapy. For every increase of 1  week in gestational age 
from 36 to 40 weeks, the odds of necessity of morphine 
therapy increases 88  %. For every increase of one kg in 
birth weight, the odds of necessity increase 3.1 times. For 
every increase of 5 ng/ml in norbuprenorphine concen-
tration, the odds of necessity increase 92  %. For every 
increase of 5  ng/ml in buprenorphine-glucuronide con-
centration, the odds of necessity decrease 54 %.
As shown in Table 3, multiple logistic regressions were 
conducted for norbuprenorphine and buprenorphine-
glucuronide concentration in cord blood. Maternal 
daily buprenorphine dose, cord blood buprenorphine 
and norbuprenorphine-glucuronide concentration were 
not included since they were not associated with mor-
phine therapy necessity based on simple logistic regres-
sion modeling. Gestational age and birth weight were 
not selected for the final model since they are corre-
lated. The adjusted odds ratios for norbuprenorphine is 
2.504, which indicates that for every increase of 5  ng/
ml in norbuprenorphine cord blood concentration the 
odds of morphine therapy need increases 2.5 times, con-
trolling for buprenorphine-glucuronide. On the other 
hand, the adjusted OR for buprenorphine-glucuronide 
is 0.423, which indicates that for every increase of 5 ng/
ml in buprenorphine-glucuronide, the odds of necessity 
decreases 57.7 % controlling for norbuprenorphine.
Table 1 Sample descriptive statistics (N = 19)
Parameter Mean (SD)
Duration of NICU stay (days) 6.5 (9.2)
Duration of morphine therapy (days) 5.1 (8.3)
Gestational age (weeks) 38.5 (1.4)
Birth weight (kg) 2.9 (0.39)
Maternal daily buprenorphine dose (mg) 11.2 (6.3)
Buprenorphine concentration (ng/ml) 9.0 (6.7)
Norbuprenorphine concentration (ng/ml) 13.9 (7.8)
Buprenorphine-glucuronide concentration (ng/ml) 14.0 (8.2)
Norbuprenorphine-glucuronide concentration (ng/ml) 23.3 (15.5)
Table 2 Sample descriptive statistics and  outcomes of  simple logistic regression analyses examining relation-
ships between  buprenorphine and  metabolite cord blood concentrations and  neonate and  maternal characteristics, 
and necessity (yes/no) of morphine replacement therapya (N = 19)
OR odds ratio, 95 % CI 95 % confidence interval around odds ratio
a A statistically significant adjusted odds ratio greater than 1 indicates increased odds of morphine replacement therapy necessity/NICU transfer
Parameter Mean (SD) Morphine replacement therapy necessity
OR (95 % CI) Effect size
Duration of NICU stay (days) 6.6 (9.2) NA NA
Duration of morphine therapy (days) 5.1 (8.3) NA NA
Gestational age (weeks) 38.5 (1.4) 1.88 (0.12–29.78) 0.35
Birth weight (kg) 2.9 (0.39) 3.10 (0.23–42.65) 0.63
Maternal daily buprenorphine dose (mg) 11.2 (6.3) 1.01 (0.87–1.18) 0.01
Buprenorphine concentration (ng/ml) 9.0 (6.7) 0.97 (0.83–1.12) 0.01
Norbuprenorphine concentration (ng/ml) 13.8 (8.0) 1.92 (0.86–4.16) 0.36
Buprenorphine-glucuronide concentration (ng/ml) 14.0 (8.2) 0.46 (0.20–1.06) 0.43
Norbuprenorphine-glucuronide concentration (ng/ml) 23.3 (15.5) 0.98 (0.92–1.04) 0.01
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Discussion
Fetal outcomes resulting from maternal opioid expo-
sure depend on multiple variables, resulting in uncer-
tainty of development of NAS in the newborn (Malek 
and Mattison 2011). Recent literature suggests 22–67  % 
infants present with NAS when prenatally there is a his-
tory of buprenorphine intake (Lacroix et  al. 2011; Patel 
et  al. 2013; Welle-Strand et  al. 2012). In our study, that 
incidence is 36  % (7/19), which is in the range of what 
has been previously reported. However, the wide range 
of reported NAS incidence with buprenorphine use is 
indicative of the unpredictability of this syndrome follow-
ing maternal use of buprenorphine. One factor that may 
contribute to this range includes variability in buprenor-
phine pharmacokinetics associated with CYP3A and 
CYP2C8, with heightened variation in CYP3A during 
pregnancy (Elkader and Sproule 2005; Lewis and Dinh 
2015). Additionally, CYP2C8 is thought to be highly 
inducible, whereas the UGT isozymes responsible for 
Phase II metabolite formation may be less affected by 
pregnancy, thus implying a higher burden of active drugs 
with reduced conjugation (Isoherranen and Thummel 
2013; Lewis and Dinh 2015). Metabolism within the 
placenta may also play a significant role in variations in 
fetal drug exposure to buprenorphine. Conversion of 
buprenorphine by aromatase (CYP19) to active norbu-
prenorphine increases with gestational age, thus support-
ing our results tying birth weight and gestational age to 
the development of NAS (Fokina et al. 2011), and CYP19 
expression in syncytiotrophoblasts has been shown to 
be subject to genetic variation (Kumar and Mendel-
son 2011). Another possibility for explaining differences 
in NAS treatment needs lies in the individual infant’s 
expression of P-glycoprotein, an efflux transporter pre-
sent in the placenta. Nekhayeva et  al. (2006) demon-
strated that this transporter is active against the parent 
drug, buprenorphine, among other xenobiotics. Finally, 
the impact of single nucleotide polymorphisms (SNPs) 
in opioid disposition genes has been investigated to 
reveal that variants in the OPRM1 118A>G and COMT 
158A>G may be linked to lower NAS severity (Wachman 
et al. 2013).
To our knowledge, this is the largest study to date that 
has looked at umbilical cord plasma level of buprenor-
phine and its metabolites, to correlate these quantitative 
markers with neonatal course in NAS. Previous work by 
Conchiero and colleagues showed that buprenorphine 
metabolite concentrations could not predict the devel-
opment of NAS (n = 5) (Concheiro et al. 2010a, b). Our 
data, although also limited by a small sample size, sug-
gest that norbuprenorphine and the inactive glucuro-
nide conjugate of buprenorphine can be useful in this 
respect. These data are in line with evidence presented in 
a review by Lewis et al., indicating a higher rate of active 
norbuprenorphine in infants of higher gestational age 
(Fokina et al. 2011; Lewis and Dinh 2015). Some investi-
gators have suggested sex differences in NAS manifesta-
tion, with males showing NAS more often than females; 
however we were not able to explore this further due to 
our small sample size (O’Conner et al. 2013). We are in 
infancy of learning regarding genetic interplay of mater-
nal, placental, and infant’s milieu with regard to maternal 
ingestion of opioid and resulting fetal effects. We propose 
that the investigation of metabolites in cord blood may 
be a practical way to study NAS in the buprenorphine 
exposed population, as these metabolites represent the 
end outcome of enzymatic and genetic variability in the 
maternal-placental-fetal triad.
Results from the MOTHER study (The Maternal Opi-
oid Treatment: Human Experimental Research) show no 
relationship between maternal buprenorphine dose and 
the severity of NAS (Jones et  al. 2012). Similar results 
were found in our study. No statistical significance was 
shown in regards to maternal buprenorphine dose at 
the time of delivery or the calculated cumulative dose 
throughout pregnancy with length of stay or duration of 
treatment required. Increasing birth weight and gesta-
tional age found to be strongly associated with develop-
ment of NAS which can be explained by more conversion 
of buprenorphine to norbuprenorphine by aromatase by 
placental tissue, whose expression increases with gesta-
tional age from 16 to 24 km from 27–33 to 34–37 weeks 
(Fokina et  al. 2011). Maternal history at delivery was 
taken as ‘evidence’ for maternal drug treatment, rather 
than followed by a confirmatory urine drug test. This dis-
crepancy may have affected our results, as research has 
shown that ‘history of drug use’ is not the best marker for 
drug use in pregnancy (Ostrea et al. 2001).
Liquid-chromatography with mass spectrometric 
detection (LC–MS) has been successfully applied to the 
Table 3 Multiple logistic regression modeling of morphine replacement therapy necessity (yes/no) across norbuprenor-
phine and buprenorphine-glucuronide cord blood concentration
aOR adjusted odds ratio, 95 % CI 95 % confidence interval around odds ratio
Variable B coefficient Standard error aOR 95 % CI Effect size
Norbuprenorphine (5 ng/ml) 0.918 0.575 2.504 0.812–7.726 0.507
Buprenorphine-glucuronide (5 ng/ml) −0.860 0.448 0.423 0.176–1.019 0.475
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study of buprenorphine concentrations in urine, plasma, 
hair, sweat, and breast milk (Gray and Huestis 2007). 
Some groups have concentrated on pregnancy specific 
matrices such as umbilical cord tissue and meconium to 
quantify in utero exposure to these drugs (Kacinko et al. 
2008a, b; Concherio et al. 2009; Concheiro-Guisan et al. 
2009). The LC–MS method used in this study is adapted 
from these previous studies, all of which were sup-
ported by the National Institute on Drug Abuse (NIDA), 
a trusted source for drug analysis. Our method shows 
similar limits of quantification for buprenorphine, norbu-
prenorphine, and the glucuronide conjugates (Kyle et al. 
2015). The importance of monitoring buprenorphine 
metabolites in this study cannot be underestimated. In a 
2009 study by Kacinko et  al. (2009), the glucuronidated 
version of norbuprenorphine was shown to be the pri-
mary urinary metabolite for pregnant women in their 
third trimester, indicating that the ability to measure this 
metabolite in the cord blood would be key to getting a 
full picture of neonatal exposure.
Recent study has suggested that cord tissue is equiva-
lent and may be a superior matrix compared to meco-
nium in detecting maternal drug exposure to cocaine, 
alcohol and amphetamines (Kacinko et al. 2008a, b). Our 
hospitals have utilized umbilical cord tissue for screening 
of maternal drug use as a routine and standard care when 
there is a history of maternal drugs or clinical suspicion 
based on maternal history or newborn’s course. Umbili-
cal cord tissue gives only concentration of buprenorphine 
and norbuprenorphine when present but not buprenor-
phine-glucuronide and norbuprenorphine-glucuronide 
metabolite. Umbilical cord plasma is considered a rela-
tively ‘new’ matrix useful for investigating in utero drug 
exposure, and limited head-to-head comparisons with 
cord tissue have been initiated (Gray and Huestis 2007) 
Both cord plasma and cord tissue have the advantage 
of being immediately available following delivery, and 
require a non-invasive collection (Gray and Huestis 
2007). Our results indicate a false negative rate of 37  % 
using the cord tissue as the analytical matrix to exam-
ine the buprenorphine exposure, and of those “negative” 
samples, 57 % tested for norbuprenorphine-glucuronide 
as the highest opioid marker when the cord blood was 
analyzed. Only 63  % of neonates exposed to maternal 
buprenorphine in this study had positive cord tissue lev-
els compared to 100 % having positive metabolite concen-
trations in cord blood. Other investigators have shown 
that the glucuronide conjugates can indeed be quanti-
fied in the cord tissue, but the drug concentrations are 
much lower than in cord blood and meconium, making 
this a much less sensitive matrix to monitor drug expo-
sure to the neonate (Concheiro et al. 2010a, b). The lower 
sensitivity for cord tissue in monitoring glucuronide 
metabolites is likely related to the high water solubility 
of these conjugates, making them less likely to partition 
into tissue (Brunton et al. 2011). The institution’s cord tis-
sue assay used in tandem with our study did not monitor 
for metabolite levels, and therefore, we found that LC–
MS analysis of the cord blood with metabolite monitor-
ing was superior to cord stat analysis without metabolite 
monitoring.
Limitations
A limitation of our study is the small sample size (n = 19). 
It is unlikely to find significant associations between 
buprenorphine and buprenorphine-metabolite concen-
trations in cord blood and the need to initiate morphine 
replacement therapy in drug-exposed neonates at sig-
nificance level α  =  0.05 given such small sample size. 
According to statistical theory, p values related to ORs or 
regression coefficients depend on sample size. Large sam-
ples can lead to small p values without resulting in practi-
cal significance (e.g., statistical significance does not imply 
practical significance). On the other hand, small samples 
can lead to large p values without resulting in practical 
non-significance (e.g., statistical non-significance does 
not imply practical non-significance). Therefore, we used 
effect size (ES) converted from OR, rather than p values 
related to ORs or regression coefficients to assess the 
association between the dependent variable and those 
predictors since ES does not depend on sample size.
Conclusions
In an examination of a small number of neonates with 
a history of in utero exposure to buprenorphine, we 
found a trend of an inverse relationship between cord 
blood concentrations of buprenorphine-glucuronide, 
and a positive relationship between cord blood concen-
trations of norbuprenorphine, which can help predict 
morphine treatment necessity along with birth weight 
and gestational age. Additionally, we found that glucu-
ronide conjugate metabolite quantification via LC–MS 
in cord blood samples from these patients is essential in 
preventing false negative results that appear when only 
buprenorphine and norbuprenorphine are measured in 
cord tissue. This has implications for improving patient 
care along with significant reduction in patient care cost 
if proven in larger study.
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